Rahman M M, Haque S S, Rokeya B, Siddique M A, Banerjee S K, Ahsan S A, Rahman F, Mahmood M, Ahmed K, Bhuiyan M M, Joarder A I, Debnath R C
Department of Cardiology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh.
Mymensingh Med J. 2012 Apr;21(2):292-9.
This prospective randomized, controlled trial was done to evaluate the efficacy of trimetazidine in the prevention of contrast induced nephropathy in patients with raised serum creatinine levels undergoing coronary angiogram. This study was performed in the Department of Cardiology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh from April 2009 to March 2010. Contrast-induced nephropathy (CIN) is a serious complication of coronary angiography that is associated with considerably increased mortality and morbidity, including the need for short-term haemodialysis, extended hospitalisation and permanent impairment of renal function. Trimetazidine (TMZ) has been described as a cellular anti-ischaemic agent. This study was trial with 400 patients. Among them 200 patients treated with trimetazidine plus hydration with normal saline and 200 patients (control) given hydration by normal saline only. It was found that the incidence of CIN was significantly (p<0.05) reduced by trimetazidine administration with saline in comparison with saline alone in patients undergoing coronary angiogram (4% vs. 14%).
这项前瞻性随机对照试验旨在评估曲美他嗪在预防血清肌酐水平升高且接受冠状动脉造影的患者中对比剂诱导的肾病的疗效。本研究于2009年4月至2010年3月在孟加拉国达卡的班加班杜·谢赫·穆吉布医科大学心脏病学系进行。对比剂诱导的肾病（CIN）是冠状动脉造影的一种严重并发症，与死亡率和发病率显著增加相关，包括需要短期血液透析、延长住院时间和肾功能永久性损害。曲美他嗪（TMZ）被描述为一种细胞抗缺血药物。本研究对400例患者进行了试验。其中200例患者接受曲美他嗪加生理盐水水化治疗，200例患者（对照组）仅接受生理盐水水化治疗。结果发现，在接受冠状动脉造影的患者中，与单独使用生理盐水相比，曲美他嗪联合生理盐水给药可显著降低CIN的发生率（p<0.05）（4%对14%）。
